🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New #UROwebinar by Profs. Paolo Gontero, Hugh Mostafid & Van Rhijn next week! Learn about new system that uses data from a large series of Ta-T1 NMIBCs & able to stratify pts w/ progression rate from 1% (low risk) to 40% (very high risk). Register now👉ow.ly/wnZC50IbqaJ

Thanks Olympus Medical UKIE for sharing this #HealthcareConvo about our top three priorities for #BladderCancer diagnosis, treatment and care. Would you add anything else to the list? #BladderCancerAwareness #CancerAwareness Hugh Mostafid

Congratulations ⁦🇮🇳 Bhavan Rai 🇬🇧⁩ ⁦Imran Omar⁩ ⁦Hugh Mostafid⁩ & co on this important systematic review of incidence & risk factors for urothelial ca & RCC in #haematuria #hematuria 👏🏻 Building evidence to improve our diagnostic pathways 💪🏻 sciencedirect.com/science/articl…

Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria buff.ly/3Kw43zm 🇮🇳 Bhavan Rai 🇬🇧 Imran Omar Hugh Mostafid Viktor Soukup Philippe Violette

Come join us in August for our inaugural workshop on Endoscopic Bladder Cancer Surgery WGH Connect #EBCSatEBCS Jo Cresswell Prof Param Mariappan 🇬🇧 🇲🇾 Hugh Mostafid @PelvicERAS Prashant Patel KARL STORZ - UK @PhotocureAS medac Pharma BSoT ..and Enjoy The Edinburgh Festival!

#EAU22 Join us next Saturday for a terrific #ESOU #ERUS #ESUT session on controversies in uro-oncology Crème de la crème faculty, hot debates and interaction! It'll be great fun to chair live with 🇫🇷 Morgan Roupret & 🇪🇸Carme Mir after some time! You wouldn't want to miss it!

Enjoyed presenting a didactic course: 'How to proceed with hematuria' w/ Hugh Mostafid at the #EAU22 meeting. Great interactive discussion on evaluation and management of hematuria ranging from asymptomatic microscopic hematuria to hemorrhagic cystitis. Mayo Clinic Urology

Hyperthermic chemo does not improve DFS in intermediate risk NMIBC: DFS @ 24 mos: 61% vs 60% Conclusive results from HIVEC-II RCT : led by Wei Shen Tan while at @UCLH - now Society of Urologic Oncology MD Anderson Cancer Center Hugh Mostafid Rami Issa Barts Cancer Institute (Queen Mary) European Urology sciencedirect.com/science/articl… #bladdercancer

10/ Massive thanks to the team Hugh Mostafid Prof Param Mariappan 🇬🇧 🇲🇾 Newcastle University @NCL_medresearch The ICR Prof Emma Hall @hsru_aberdeen gsmaclennan James N'Dow University of Aberdeen Matt Breckons Giovany Orozco Leal | BLM 🇨🇴 Jo Cresswell Dr Emma Clark John Kelly UCLH Robotics @ZaferTandogdu

Iranian women are among the most educated and accomplished around the world. Help support the movement #mahsaamini #womenofiran #womensrights #iranpotests instagram.com/p/CjN0fKorqXJ/…

Happy to share our preprint investigating chemoablation in recurrent non-muscle invasive bladder cancer. ⁦Journal of Clinical Oncology⁩ ⁦Jørgen Bjerggaard⁩ ⁦Lars Dyrskjøt⁩ ⁦Nessn Azawi⁩ ascopubs.org/journal/jco

I have used this strategy in patients unable to undergo TURBT (eg recovering from acute MI) or to debulk certain tumors prior to TURBT Hugh Mostafid jim catto Joan Palou Redorta Gary Steinberg Wes Kassouf Stephen B. Williams, MD, MBA, MS, FACHE Maria J. Ribal Angie Smith Morgan Roupret Petros Grivas IBCG

The evidence for role of neoadjuvant therapy in NMIBC continues to mount 2 doses of NAC with MMC reduced risk of recurrence by 63%: Journal of Urology auajournals.org/doi/10.1097/JU… Intensive MMC – 3/wk x 2 wks – reduced need for TURBT in 57% patients sciencedirect.com/science/articl… #BladderCancer

Editor Pick: Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours buff.ly/30gMH3m Hugh Mostafid Ashish M. Kamat, MD, MBBS Joan Palou Redorta james mckiernan jim catto #bladdertumours #MedTwitter #urology

Bladder Cancer Review: Epidemiology, Screening, and Prevention of Bladder Cancer buff.ly/3FQ5Izv Niyati Lobo Luca Afferi Marco Moschini Hugh Mostafid Sima Porten Sarah P. Psutka MD MS Shilpa Gupta Angie Smith Stephen B. Williams, MD, MBA, MS, FACHE #bladdercancer #review #UroOnco #MedTwitter

Editor's Choice: Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours euoncology.europeanurology.com/article/S2588-… Hugh Mostafid Ashish M. Kamat, MD, MBBS Sia Daneshmand, M.D. Joan Palou Redorta james mckiernan jim catto #Editorschoice #bladder #UroOnco

Thrilled that active surveillance for #BladderCancer has made it into #EAU23 Guidelines European Association of Urology (EAU) Paolo Gontero Morgan Roupret Watch out for data from Wei Shen Tan IBCG Roberto Contieri Valentina Grajales MD, MS MD Anderson Cancer Center on this topic YUO Amer. Urol. Assn. Bladder Cancer Advocacy Network Society of Urologic Oncology

Came across this by chance in Dubai - never realised that an NHS hospital had a ‘branch’ in Dubai + proudly boasts that many of the staff are recruited from the NHS. At a time of long w/lists, bed waits and low morale not sure this is what our NHS hospitals should be supporting.